Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo® Use at ASH 2023 : vimarsana.com

Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo® Use at ASH 2023

/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will be presenting new data in acute...

Related Keywords

United States , Boston , Massachusetts , American , Arjun Prasad , Prnewswire Servier , Becky Martin , Nathan Mellor , American Society Of Hematology , Servier Group , European Union , Servier Pharmaceuticals , American Society , Annual Meeting , Diagnosed Acute Myeloid Leukemia , Refractory Myelodysplastic Syndromes , Interval Prolongation , Prolonging Drugs ,